HeshamGayarMD

Medical Director, McLaren Proton Therapy, Karmanos Cancer Institute; Chairman Radiation Oncology, McLaren Flint; Chairman Clinical Leadership Council, Karmanos Cancer Institute; Associate Medical Director, Karmanos Cancer Institute; Chairman Research Advisory Board, McLaren Health Care

Join to view full profile

Dr. Gayar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Gayar's full profile

Already have an account?

Office
McLaren Proton Therapy Center
4100 Beecher Rd
Flint, MI 48532
Phone+1 810-342-3840

Fax+1 810-342-4229
Is this information wrong?

Summary

Hesham Gayar, M.D., a board certified radiation oncologist, is Medical Director for the McLaren Proton Therapy Center, part of the Karmanos Cancer Network. He also serves as Vice President for the Particle Therapy Co-Operative Group (PTCOG) -North American Chapter and as a board member and Steering Committee member for PTCOG worldwide. His involvement in proton therapy also includes membership on the Executive Committee of the Proton Collaborative Group Medical Societies and as a member of the World Forum on Particle Therapy Strategic Planning for 2030.

Dr. Hesham Gayar - Advantages of Proton Radiation

Dr. Hesham Gayar, Medical Director of the McLaren Proton Therapy Center in Flint, Michigan, explains the advantages of proton therapy for certain cancer site...

Meet Dr. Hesham Gayar - Radiation Oncology | Karmanos Cancer Institute

Hesham Gayar, M.D., MBChB, chairman of Radiation Oncology at Karmanos Cancer Institute at McLaren Flint and a member of the Genitourinary Multidisciplinary Team

McLaren Proton Therapy Center

Dr. Hesham Gayar discusses the innovative cancer treatment option available at McLaren Proton Therapy Center in Flint, Michigan.

Education & Training

MD Anderson Proton Therapy CenterObservership, 2012 - 2012
Ohio State University HospitalFellowship, Hematology and Medical Oncology, 1986 - 1987
New York Medical College at Westchester Medical CenterResidency, Radiation Oncology, 1983 - 1986
Alexandria University Faculty of MedicineClass of 1980, MD, MBChB, High Honors

Certifications & Licensure

MI State Medical License 1990 - 2024
NC State Medical License 2021 - 2024
IL State Medical License 1987 - 1996
American Board of Radiology Radiation Oncology

Clinical Trials

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2009 Sep 01
Active, not recruiting
Phase 3
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2011 Jul 01
Active, not recruiting
Phase 3
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer Start of enrollment: 2012 May 01
Active, not recruiting
Phase 3
Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer Start of enrollment: 2013 Apr 01
Active, not recruiting
Phase 3
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery Start of enrollment: 2013 Aug 01
Active, not recruiting
Not Applicable
Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy Start of enrollment: 2014 Feb 07
Active, not recruiting
Phase 3
Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy Start of enrollment: 2015 Mar 28
Active, not recruiting
Phase 2
Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial Start of enrollment: 2016 Feb 01
Active, not recruiting
Not Applicable
Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Treating Patients With Limited Stage or Extensive Stage Small Cell Lung Cancer Start of enrollment: 2015 Dec 07
Active, not recruiting
Phase 2, Phase 3
Breast Cancer WEight Loss Study (BWEL Study) Start of enrollment: 2016 Aug 01
Active, not recruiting
Phase 3
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC). Start of enrollment: 2016 Jul 01
Active, not recruiting
Phase 3
Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer Start of enrollment: 2017 Jan 11
Completed
Phase 2
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy Start of enrollment: 2016 Dec 08
Terminated
Phase 3
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery Start of enrollment: 2017 Jan 16
Active, not recruiting
Phase 2, Phase 3
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer Start of enrollment: 2017 Apr 07
Active, not recruiting
Phase 2
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer Start of enrollment: 2018 Jul 05
Active, not recruiting
Phase 3
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin Start of enrollment: 2018 Apr 03
Active, not recruiting
Phase 2, Phase 3
Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer Start of enrollment: 2017 Nov 16
Active, not recruiting
Phase 3
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer Start of enrollment: 2018 Mar 12
Active, not recruiting
Phase 3
A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer Start of enrollment: 2018 Jul 05
Active, not recruiting
Not Applicable
Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), The ARCHON-1 Trial Start of enrollment: 2019 Oct 28
Recruiting
Phase 1
A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery Start of enrollment: 2019 Apr 15
Active, not recruiting
Phase 2
Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation Start of enrollment: 2019 Mar 06
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

20 citations
Radium-223 in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer
Dipenkumar Modi, Clara Hwang, Hirva Mamdani, Seongho Kim, Hesham Gayar, Ulka N. Vaishampayan, Richard Joyrich, Elisabeth I. Heath> ;Clinical Genitourinary Cancer. 2016 Oct 1
1 citations
SU‐E‐T‐561: A Comparative Study of Single Verses Two Field Daily Fraction for Treatment of Prostate Cancer Using IMPT, Double‐Scattered, and SUFD Delivery Technique
B. Arjomandy, T. Schultz, Sung Yong Park, H. Gayar> ;Medical Physics. 2012 Jun 1

Journal Articles

Angiosarcoma of the Breast Following Lumpectomy and Radiation Therapy for Breast Carcinoma: Case Report and Review of the Literature
Timmer, SJ; Osuch, JR; Colony, LH; Edminster, RR; Gayar, HE and Ingram, R, The Breast Journal, 1/3/1997

Abstracts/Posters

Use of radium-223 in heavily pretreated metastatic castrate resistant prostate cancer (mCRPC) patients
Gayar, H., Genitourinary Cancers Symposium, 2015
Comparison of survival and nodal staging in rectal cancer patients undergoing sentinel lymph node mapping versus conventional surgery
Saha, S; Berbiglia, L; Koduru, U; Johnston, G; Dhar, VK; Burke, J; Nettleton, J; Devisetty, K; Gayar, H; Sing, T; Arora, ML, Journal of Clinical Oncology, 3/2014

Lectures

McLaren Health Care Proton Treatment Center: A Lower-Cost, Breakthrough Technology Center in Michigan
50th Conference of the Particle Theory Co-Operative Group - Philadelphia, PA - 5/2011
Clinical Outcomes of Inoperable, Early Stage, Non-Small Cell Lung Cancer Patients Treated with Image Guided Stereotactic Body Radiation Therapy Delivered by Helical To...
52nd American Socieity for Radiation Oncology Conference - San Diego, CA - 11/2010
Patterns of Recurrence and Nodal Staging in Rectal Cancer Patients Undergoing Sentinel Lymph Node Mapping Compared to Conventional Surgery
51st American Society for Radiation Oncology Conference - Chicago, IL - 2009
Clinical Outcome of Early Stage Non-Central, Non-Small Cell Lung Cancer Patients Treated with Image Guided Stereotactic Body Radiotherapy (IG-SBRT) Delivered by Helica...
1st Sino-American Network of Therapeutic Radiology & Oncology Symposium - Grand Epoch City, China - 2008
Stereotactic Radiosurgery and Radiotherapy
Jeddah Oncology Conference - Saudi Arabia - 2005
Prognostic Factors in Relation to Recurrent Endometrial Cancer: A Prospective Analysis
American Society of Clinical Oncology Annual Meeting - 2001
Join now to see all

Other

Results of Novel Multi-channel HDR Brachytherapy Applicators in the Treatment of Non-melanoma Skin Cancer
Gayar, H; Devisetty, K; Sharma, VK; Gayar, K; Dillon, T; Gaffney, K; Soderstrom, R; Khan, F and Nettleton, JL, American Society for Radiation Oncology
2/2014

Press Mentions

UK Trial Asks if Proton Beam Therapy for Breast Cancer Can Reduce Heart RisksJanuary 9th, 2023
Fellowship-Trained Proton Therapy Specialist, Radiation Oncologist Joins McLarenSeptember 16th, 2021
Radiation Oncologist Joins McLaren Proton Therapy Center TeamAugust 27th, 2020
Join now to see all

Committees

Member, Steering Committee (Particle Therapy Co-Operative Group - Worldwide)
Member, Education Sub-committee (Particle Therapy Co-Operative Group - International)

Professional Memberships

Particle Therapy Co-Operative Group - North America
Vice President
Particle Therapy Co-Operative Group - Worldwide
Board Member
Genesee County Medical Society
Board of Directors Member, Former President
Michigan State Medical Society
Delegate
Particle Therapy Co-Operative Group - International
Member

Hospital Affiliations

McLaren Lapeer RegionLapeer, Michigan
Memorial HealthcareOwosso, Michigan
McLaren Greater LansingLansing, Michigan
McLaren FlintFlint, Michigan
Karmanos Cancer CenterDetroit, Michigan

Industry Relationships

Member, Michigan Governor Advisory Board for the Commission on Arab and Chaldean American Affairs
Board Member, Grand Blanc Islamic Center
Board Member, Flint Islamic Center
Board Member, Arab American Heritage Council - Flint
Board Member, McLaren Flint Foundation

External Links

McLaren Physician Profilehttps://www.mclaren.org/main/physician-directory/gayar-hesham-1461
McLaren Proton Therapy Centerhttp://www.mclaren.org/protontherapy
Karmanos Cancer Institutehttps://www.karmanos.org/karmanos/karmanos-home